This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don’t share our data with other parties. Read more about our cookie policy

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Read more about our cookie policy

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

Postdoc Developing Combination targeted- and immuno-therapies

Your function within the department

The NKI, located in Amsterdam, is the only comprehensive cancer center in The Netherlands. It is a well-organized and dynamic institute accommodating over 50 research groups and many advanced core facilities. It is an internationally renowned center covering fundamental, translational and clinical cancer research.
The Peeper lab has a strong track record in function-based genomics to aid the development of more durable clinical responses for cancer patients. We aim to identify specific tumor vulnerabilities for drug target and biomarker discovery and subsequently set up for clinical implementation, in close collaboration with our clinical colleagues.

To reach these goals, we develop and utilize in vitro and in vivo genome-wide functional perturbation screens for a better understanding of tumor heterogeneity and drug resistance as well as for the identification of factors amenable to pharmacologic intervention and predictive biomarkers. This is done for several cancer types including melanoma, lung and breast cancer. Given the advances made for immunotherapy, we have also established systems allowing for including immunological factors in our genetic screens. Candidate genes are assessed and ranked computationally and subsequently functionally validated in clinically relevant models, including patient-derived xenografts. Many of these elements will be covered in this project, aiming to develop novel treatment strategies.

Your profile

We seek a highly ambitious postdoc. Experience in molecular cancer biology and/or immunology is recommended, as is a desire to translate your findings to the clinic.

Your career opportunities and terms of employment

You will be employed for a period of at least 3 years. The gross salary per month is € 3.363,- to € 3.774,- and depends on previous experience. The terms of employment will be in accordance with the CAO Hospitals.
For more information please contact prof. Daniel Peeper, Division of Molecular Oncology, Netherlands Cancer Institute, Amsterdam.
E-mail: (don’t use this to apply).

Select reading
- Kemper et al., BRAFV600E kinase domain duplication identified in therapy-refractory melanoma patient-derived xenografts. Cell Rep 2016
- Kemper et al., Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. EMBO Mol Med 2015
- Kuilman, T. et al. CopywriteR: DNA copy number detection from off-target sequence data. Genome
  Biol 2015
- Possik et al., Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality
  between hypoxia and DNA Damage Response inhibition. Cell Rep 2014
- Muller et al., Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
  Nature Comm 2014
- Kaplon et al., A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced
  senescence, Nature 2013